Remove Antibody Remove Immune Response Remove Life Science
article thumbnail

World Pneumonia Day 2024: New Treatments and Innovations

XTalks

World Pneumonia Day 2024 provides an opportunity to examine the latest advances in pneumonia treatment and prevention — and the role that healthcare and life sciences industries play in reducing its global impact. For instance, suvratoxumab, a monoclonal antibody targeting S.

Bacteria 110
article thumbnail

2021 Year in Review: Leveraging New Technologies to Drive Innovation in the Life Sciences

XTalks

Xtalks is taking a look at some of the major stories and innovations of the year in the life sciences, many of which were driven by new, emerging and improved technologies. The year 2021 was all about continuing innovations in the life sciences. Life Science Innovations: Malaria and Influenza Vaccines.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Off-target immune response could predict COVID-19 severity

Scienmag

The presence of special immune system defense molecules, called autoimmune antibodies, has been strongly tied to how poorly people fare when hospitalized with COVID-19, a new study shows.

article thumbnail

Celltrion’s Steqeyma Approved as Stelara Biosimilar for Psoriasis

XTalks

Importantly, patients switching from Stelara to Steqeyma maintained stable anti-drug antibody (ADA) levels, demonstrating consistent immune responses to the drug over time. By blocking these inflammatory pathways, it helps manage overactive immune responses in conditions like psoriasis and Crohns disease.

article thumbnail

CanSinoBIO developed a highly effective COVID vaccine with an inhalant version

pharmaphorum

It then elicits an immune response against that spike protein. You have a response with immunoglobulins type G (antibodies) and robust cellular response with both CD4 and CD8 T-cells being activated,” Morgon states. We get a higher immune response with the inhaled compared to the injectable,” Morgon relays.

article thumbnail

Medicxi’s Portfolio Company MiroBio to be Acquired by Gilead

XTalks

Medicxi is a prominent international life sciences investment firm that invested in over 60 portfolio companies such as Versanis Bio, Rivus Pharmaceuticals, Capella Bioscience and more. One of Medicxi’s portfolio companies called MiroBio is set to be acquired by Gilead Sciences for approximately $405 million in cash.

article thumbnail

Regeneron’s COVID-19 Monoclonal Antibody Treatment First to Reduce Risk of Death in Hospitalized Patients

XTalks

This is why Regeneron’s announcement of positive clinical trial results that show its antibody cocktail treatment can cut deaths among hospitalized patients is welcome news. It is the first trial to demonstrate that any antibody treatment could improve survival in patients hospitalized with COVID-19. Regeneron Pharmaceuticals Inc.’s